"I have not followed every opportunity that came along in my career," says Thomas Werlen, general counsel of Swiss pharmaceutical firm Novartis. "But in hindsight I was right not to, and I have also been right about the opportunities I have pursued." Werlen is referring, in the first instance, to the offers he passed up in the 1990s as a junior lawyer with New York leader Cravath Swaine & Moore to move into investment banking ("short term, it would have been great money; long term, it would have hindered my development as a lawyer") and, more recently, to his decision to leave Allen & Overy's (A&O's) London office three years ago to take up his current position.
Novartis GC Thomas Werlen talks to Alex Aldridge about the overhaul of the Swiss pharmaceutical giant's legal team, its external law firm relationships and escaping the billable hour "I have not followed...
What are the pros and cons of using a limited liability partnership structure?
Pinsent's tops the AIM adviser ranking table, acting for 55 clients
Baker Botts and Keystone Law pick up one KWM partner apiece as eight partners leave the partnership
UK firm adds new practice area to its Paris office, which is currently being run out of London by managing partner Sharon White
Listed firm adds four new partners in 2016 promotions round, up from two last year prior to its flotation